Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EBIT (2016 - 2025)

Editas Medicine (EDIT) has disclosed EBIT for 11 consecutive years, with -$24.5 million as the latest value for Q3 2025.

  • Quarterly EBIT rose 62.62% to -$24.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$198.8 million through Sep 2025, up 12.98% year-over-year, with the annual reading at -$251.2 million for FY2024, 48.45% down from the prior year.
  • EBIT for Q3 2025 was -$24.5 million at Editas Medicine, up from -$51.5 million in the prior quarter.
  • The five-year high for EBIT was -$24.0 million in Q4 2023, with the low at -$76.2 million in Q1 2025.
  • Average EBIT over 5 years is -$53.6 million, with a median of -$54.2 million recorded in 2022.
  • The sharpest move saw EBIT crashed 94.45% in 2024, then skyrocketed 62.62% in 2025.
  • Over 5 years, EBIT stood at -$55.4 million in 2021, then decreased by 14.52% to -$63.4 million in 2022, then soared by 62.23% to -$24.0 million in 2023, then tumbled by 94.45% to -$46.6 million in 2024, then soared by 47.31% to -$24.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$24.5 million, -$51.5 million, and -$76.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.